A detailed history of Trexquant Investment LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 27,858 shares of SAGE stock, worth $300,309. This represents 0.01% of its overall portfolio holdings.

Number of Shares
27,858
Previous 103,097 72.98%
Holding current value
$300,309
Previous $2.23 Million 76.63%
% of portfolio
0.01%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$18.62 - $26.95 $1.4 Million - $2.03 Million
-75,239 Reduced 72.98%
27,858 $522,000
Q4 2023

Feb 09, 2024

BUY
$17.1 - $22.26 $1.76 Million - $2.29 Million
103,097 New
103,097 $2.23 Million
Q4 2022

Feb 13, 2023

SELL
$32.2 - $43.61 $43,309 - $58,655
-1,345 Reduced 6.23%
20,249 $772,000
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $697,054 - $934,372
21,594 New
21,594 $846,000
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $202,655 - $301,640
-6,599 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $244,558 - $310,878
6,599 New
6,599 $281,000
Q2 2020

Aug 07, 2020

SELL
$25.95 - $43.15 $646,077 - $1.07 Million
-24,897 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$26.15 - $77.24 $651,056 - $1.92 Million
24,897 New
24,897 $715,000
Q1 2019

May 13, 2019

SELL
$89.33 - $163.65 $193,310 - $354,138
-2,164 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$81.94 - $139.71 $111,356 - $189,865
-1,359 Reduced 38.58%
2,164 $207,000
Q3 2018

Nov 09, 2018

SELL
$138.11 - $169.04 $2.3 Million - $2.82 Million
-16,682 Reduced 82.56%
3,523 $498,000
Q2 2018

Aug 07, 2018

BUY
$140.36 - $175.76 $2.84 Million - $3.55 Million
20,205 New
20,205 $3.16 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $641M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.